Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Theriva Biologics ( (TOVX) ) just unveiled an announcement.
On June 20, 2025, Theriva Biologics, Inc. announced the filing of a prospectus supplement related to the offer and sale of up to $2,534,352 of its common stock. This move, facilitated through A.G.P./Alliance Global Partners, aims to raise capital via an at-the-market offering, with the sales agent acting as an underwriter under the Securities Act of 1933.
The most recent analyst rating on (TOVX) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Theriva Biologics stock, see the TOVX Stock Forecast page.
Spark’s Take on TOVX Stock
According to Spark, TipRanks’ AI Analyst, TOVX is a Neutral.
Theriva Biologics faces substantial financial difficulties with no revenue and growing losses, which is a major concern. While technical indicators show some short-term positive momentum, the long-term trend remains negative. The lack of profitability impacts valuation. However, the recent positive clinical trial results provide a potential future catalyst that could improve the company’s prospects.
To see Spark’s full report on TOVX stock, click here.
More about Theriva Biologics
Theriva Biologics, Inc. operates in the biotechnology industry, focusing on the development and commercialization of biologics. The company is involved in offering innovative therapeutic solutions and has a market focus on advancing its pipeline of biologic candidates.
Average Trading Volume: 1,407,671
Technical Sentiment Signal: Strong Sell
Current Market Cap: $3.69M
Find detailed analytics on TOVX stock on TipRanks’ Stock Analysis page.